FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
PO:03:033 | Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials Irene E Van Der Horst-Bruinsma1, Matthew A Brown2, Floris A Van Gaalen3, Nigil Haroon4, Lianne S Gensler5, Alexander Marten6, Myriam Manente7, George Stojan8, Thomas Vaux9, Katy White9, Atul Deodhar10, Nicola Boffini11, Martin Rudwaleit12 | 1Department of Rheumatology, Radboud University Medical Centre Nijmegen, The Netherlands; 2Genomics England London, United Kingdom; 3Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 4Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto Toronto, Canada; 5Department of Medicine/Rheumatology, University of California San Francisco, USA; 6UCB Monheim am Rhein Germany; 7UCB Braine-lAlleud, Belgium; 8UCB Atlanta, USA; 9UCB Slough, United Kingdom; 10Division of Arthritis and Rheumatic Diseases, Oregon Health and Science University Portland, USA; 11IRCCS Ospedale San Raffaele Milan, Italy; 12Klinikum Bielefeld, University of Bielefeld, Bielefeld, Germany
55 -
PO:01:011 | Achievement of Remission Defined by Absence of Objective Signs of Inflammation Versus ASDAS ID in Patients with Active Axial Spondyloarthritis Treated with Bimekizumab: 52-Week Results from Two Phase 3 Studies Lianne S Gensler1, Helena Marzo-Ortega2, Vanessa Taieb3, Diana Voiniciuc4, Alexander Marten5, George Stojan6, Mindy Kim6, Paolo Marsico7, Martin Rudwaleit8 | 1Department of Medicine/Rheumatology, University of California San Francisco, USA; 2NIHR Leeds Biomedical Research Centre, University of Leeds Leeds, United Kingdom; 3UCB Colombes, France; 4UCB Slough, United Kingdom; 5UCB Monheim am Rhein Germany; 6UCB Atlanta, USA; 7UCB Milan, Italy; 8University of Bielefeld, Klinikum Bielefeld Bielefeld Germany
58 -
PO:02:022 | Bimekizumab Maintained Stringent Clinical Responses over 2 Years in Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies Fabian Proft1, Désirée Van Der Heijde2, Sergio Schwartzman3|4|5, Joerg Ermann6, Alexander Marten7, Ute Massow7, George Stojan8, Vanessa Taieb9, Diana Voiniciuc10, Astrid Van Tubergen11, Victoria Navarro-Compán12, Simone Angioni13, Xenofon Baraliakos14 | 1Charité-Universitätsmedizin Berlin; Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; 2Department of Rheumatology, Leiden University Medical Center Leiden, The Netherlands; 3Weill Cornell Medical Center New York, USA; 4New York Presbyterian Hospital New York, USA; 5Hospital for Special Surgery New York, USA; 6Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital and Harvard Medical School Boston, USA; 7UCB Monheim am Rhein Germany; 8UCB Atlanta, USA; 9UCB Colombes, France; 10UCB Slough, United Kingdom; 11Department of Medicine, Division of Rheumatology, Maastricht University Medical Center Maastricht, The Netherlands; 12Department of Rheumatology, La Paz University Hospital, IdiPaz Madrid, Spain; 13UCB Milan, Italy; 14Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Germany
63
1 - 3 of 3 items
